Inception Return
(12/18/2020)
|
-21.75 %
|
|
YTD Return
|
-10.07 %
|
|
NAVPS
(7/14/2025)
|
$3.44
|
|
Change
|
$0.01 / 0.41 %
|
|
|
Growth of $10,000
(As of June 30, 2025)
|
|
MER
|
2.03 %
|
|
Assets ($mil)
|
-
|
|
Rank (1Yr)
|
188/191
|
|
Std Dev (3Yr)
|
-
|
|
Volatility Ranking (3Yr)
|
10/10
|
|
RRSP Eligibility
|
Yes
|
|
Load
|
Back Fee Only
|
|
Max Front End
|
3.00 %
|
|
Max Back End
|
-
|
|
Sales Status
|
Open
|
|
|
Objective
The Fund seeks short and long-term capital appreciation through the ownership of biotechnology and life sciences companies. Investments by the Fund may be made globally. The Fund may use leverage through the use of cash borrowings, short sales and derivatives.
|
Fund Manager
Next Edge Capital Corp.
Portfolio Manager
Next Edge Capital Corp.
Sub-Advisor
-
|
Allocations
Data not available
Top 10 Holdings
Performance Data
(As of June 30, 2025)
|
|
Return (%)
|
Annualized Return (%)
|
|
Return
|
1
Mth
|
3
Mth
|
6
Mth
|
YTD
|
1
Yr
|
3
Yr
|
5
Yr
|
10
Yr
|
|
Fund
|
12.54
|
13.69
|
-10.07
|
-10.07
|
-17.45
|
-18.45
|
-
|
-
|
|
Benchmark
|
2.91
|
8.53
|
10.17
|
10.17
|
26.37
|
16.09
|
15.02
|
9.61
|
|
Quartile Ranking
|
1
|
1
|
4
|
4
|
4
|
4
|
-
|
-
|
|
Calendar Return (%)
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|
Fund
|
-28.82
|
-9.41
|
-36.06
|
-14.80
|
-
|
-
|
-
|
-
|
-
|
-
|
|
Benchmark
|
21.65
|
11.75
|
-5.84
|
25.09
|
5.60
|
22.88
|
-8.89
|
9.10
|
21.08
|
-8.32
|
|
Quartile Ranking
|
4
|
4
|
4
|
4
|
-
|
-
|
-
|
-
|
-
|
-
|